A Case of Immunotherapy Response to BRAF-Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: BRAF V600E mutant NSCLC remain unclear
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The patient developed early resistance to the combination of dabrafenib and trametinib but responded well to ICI. [CONCLUSION] This case suggests that ICI may provide durable clinical benefit even after early resistance to BRAF/MEK inhibition in selected patients with high PD-L1 expression.
[INTRODUCTION] The recommended first-line therapy for BRAF V600E mutant non-small cell lung cancer (NSCLC) is a combination of dabrafenib and trametinib.
APA
Okayama Y, Tokito T, et al. (2026). A Case of Immunotherapy Response to BRAF-Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy.. Cancer reports (Hoboken, N.J.), 9(4), e70533. https://doi.org/10.1002/cnr2.70533
MLA
Okayama Y, et al.. "A Case of Immunotherapy Response to BRAF-Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy.." Cancer reports (Hoboken, N.J.), vol. 9, no. 4, 2026, pp. e70533.
PMID
41913938 ↗
Abstract 한글 요약
[INTRODUCTION] The recommended first-line therapy for BRAF V600E mutant non-small cell lung cancer (NSCLC) is a combination of dabrafenib and trametinib. Most patients respond to the initial therapy, but some show resistance in the early stages. Additionally, immune checkpoint inhibitors (ICIs) are often used after resistance develops; however, the benefits of ICIs in patients with BRAF V600E mutant NSCLC remain unclear.
[CASE PRESENTATION] We report a case of a 67-year-old man who was clinically diagnosed with lung adenocarcinoma cT2aN3M1c (BRA) stage IVB (BRAF V600E mutation-positive, programmed death-ligand 1; 90%). The patient developed early resistance to the combination of dabrafenib and trametinib but responded well to ICI.
[CONCLUSION] This case suggests that ICI may provide durable clinical benefit even after early resistance to BRAF/MEK inhibition in selected patients with high PD-L1 expression.
[CASE PRESENTATION] We report a case of a 67-year-old man who was clinically diagnosed with lung adenocarcinoma cT2aN3M1c (BRA) stage IVB (BRAF V600E mutation-positive, programmed death-ligand 1; 90%). The patient developed early resistance to the combination of dabrafenib and trametinib but responded well to ICI.
[CONCLUSION] This case suggests that ICI may provide durable clinical benefit even after early resistance to BRAF/MEK inhibition in selected patients with high PD-L1 expression.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- Proto-Oncogene Proteins B-raf
- Aged
- Pyridones
- Oximes
- Pyrimidinones
- Imidazoles
- Lung Neoplasms
- Adenocarcinoma of Lung
- Drug Resistance
- Neoplasm
- Antineoplastic Combined Chemotherapy Protocols
- Mutation
- Immune Checkpoint Inhibitors
- BRAF V600E
- PD‐L1
- dabrafenib
- immune checkpoint inhibitor
- trametinib
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.